Related Experiment Video
Updated: Mar 16, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
Zhijuan Lin1, Xing Chen2, Zhifeng Li1
1Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
Abstract:
Antibodies targeting programmed death 1 (PD-1) help prevent tumor cells from escaping immune-mediated destruction. We conducted this systematic review and meta-analysis to gain insight into the efficacy of PD-1 antibodies for the treatment of melanoma. Five trials involving 2,828 adult patients were included in this meta-analysis. In patients with previously untreated or refractory melanoma, treatment with PD-1 antibodies significantly improved the six-month progression-free survival (PFS) (HR 0.55, 95% CI 0.50-0.60, P<0.00001) and the overall response rate (OR 3.89, 95% CI 3.12-4.83, P<0.00001). This meta-analysis indicated that anti-PD-1 treatment might provide a significant survival benefit in patients with melanoma. In addition, we found that patients treated with nivolumab reported significantly fewer treatment-related adverse events (OR 0.74, 95% CI 0.57-0.97, P = 0.03) than those treated with other agents, but there was a dose-dependent increase in the frequency of adverse events in patients treated with pembrolizumab.
Insights
Programmed death 1 (PD-1) antibodies significantly improve progression-free survival and response rates in melanoma patients. This meta-analysis suggests anti-PD-1 therapy offers a survival benefit with fewer adverse events for certain treatments.
Area of Science:
- Immunology
- Oncology
- Clinical Trials
Background:
- Tumor cells can evade immune destruction.
- Programmed death 1 (PD-1) antibodies are an emerging cancer therapy.
- Melanoma treatment efficacy requires ongoing evaluation.
Purpose of the Study:
- To evaluate the efficacy of PD-1 antibodies in melanoma treatment.
- To synthesize evidence from multiple clinical trials.
- To assess survival outcomes and adverse events associated with anti-PD-1 therapy.
Main Methods:
- Systematic review and meta-analysis of five randomized controlled trials.
- Inclusion of 2,828 adult patients with melanoma.
- Analysis of progression-free survival and overall response rates.
Main Results:
- PD-1 antibodies significantly improved six-month progression-free survival (HR 0.55).
- Overall response rates were significantly higher with PD-1 antibodies (OR 3.89).
- Nivolumab showed fewer adverse events compared to other agents, while pembrolizumab had dose-dependent adverse events.
Conclusions:
- Anti-PD-1 treatment offers a significant survival benefit for melanoma patients.
- PD-1 antibodies represent a promising therapeutic strategy in oncology.
- Understanding adverse event profiles is crucial for treatment selection.
